Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1814015 | 0.80 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL1554419 | 0.77 | RIOK2 (0.57) | RIOK2NTRK1SORT1RAB9ANPC1 | |
| SCHEMBL19549753 | 0.77 | GAA (0.50) | RAB9ANPC1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL19920982 | 0.75 | CHRNB2 (0.45) | NTRK1RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL3226652 | 0.74 | EGFR (0.43) | SORT1RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL1933448 | 0.74 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL27916162 | 0.73 | RIOK2 (0.40) | RIOK2NTRK1SORT1RAB9ANPC1 | |
| SCHEMBL25223421 | 0.73 | RIOK2 (0.53) | RIOK2NTRK1SORT1RAB9ANPC1 | |
| SCHEMBL477127 | 0.73 | SMN1; SMN2 (0.53) | RIOK2NTRK1SORT1RAB9ANPC1 | |
| SCHEMBL16913891 | 0.73 | RIOK2 (0.56) | RIOK2NTRK1SORT1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321296-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | RIOK2 3333/4885NTRK1 3185/4885SORT1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.